News

Article

Warning Letter: Palace Pharmacy

Warning Letter: Compounding at Palace Pharmacy

On March 23, the US Food and Drug Administration's (www.fda.gov) Denver, CO district office sent a warning letter to Palace Pharmacy (Lander, WY) concerning the company's drug-compounding activities.

The agency expressed special concern about Palace Pharmacy'sproduction of domperidone in 10-, 15-, and 20-mg capsules for humanuse. The letter noted that domperidone (sometimes used to increaseprolactin levels and improve breast milk production) is not approvedfor any human use in the United States, is not approved for enhancing lactation inany country, and has cardiovascular side effects that have forced itswitdrawal from the market in several countries where it had beenapproved to treat gastric stasis and gastropaiesis.

FDA warned Palace that the current domperidone label "fails to bearadequate direction for their use" and that the products themselves areunapproved drugs under 21 CFR § 201.115.

–Douglas McCormick

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content